We first tested a panel of EGFR‐mutated cell lines for their ERK and AKT phosphorylation status, two key actors of the EGFR signaling pathway involved in the sensitivity of tumor cells to EGFR‐TKI (Niederst & Engelman, 2013). Here, EGFR is linked to neoplasm.